BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Russo A, Li P, Strong VE. Differences in the multimodal treatment of gastric cancer: East versus west. J Surg Oncol 2017;115:603-14. [PMID: 28181265 DOI: 10.1002/jso.24517] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Padmanabhan N, Ushijima T, Tan P. How to stomach an epigenetic insult: the gastric cancer epigenome. Nat Rev Gastroenterol Hepatol 2017;14:467-78. [DOI: 10.1038/nrgastro.2017.53] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 12.6] [Reference Citation Analysis]
2 Wang J, Lv B, Su Y, Wang X, Bu J, Yao L. Exosome-Mediated Transfer of lncRNA HOTTIP Promotes Cisplatin Resistance in Gastric Cancer Cells by Regulating HMGA1/miR-218 Axis. Onco Targets Ther 2019;12:11325-38. [PMID: 31908497 DOI: 10.2147/OTT.S231846] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
3 Wu L, Ge L, Qin Y, Huang M, Chen J, Yang Y, Zhong J. Postoperative morbidity and mortality after neoadjuvant chemotherapy vs upfront surgery for locally advanced gastric cancer: a propensity score matching analysis. Cancer Manag Res. 2019;11:6011-6018. [PMID: 31308742 DOI: 10.2147/cmar.s203880] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Lieto E, Galizia G, Auricchio A, Cardella F, Mabilia A, Basile N, Del Sorbo G, Castellano P, Romano C, Orditura M, Napolitano V. Preoperative Neutrophil to Lymphocyte Ratio and Lymphocyte to Monocyte Ratio are Prognostic Factors in Gastric Cancers Undergoing Surgery. J Gastrointest Surg. 2017;21:1764-1774. [PMID: 28752404 DOI: 10.1007/s11605-017-3515-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
5 Huang B, Chang C, Wang BL, Li H. ELK1-induced upregulation of lncRNA TRPM2-AS promotes tumor progression in gastric cancer by regulating miR-195/ HMGA1 axis. J Cell Biochem 2019;120:16921-33. [PMID: 31104318 DOI: 10.1002/jcb.28951] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
6 Bang YJ, Van Cutsem E, Fuchs CS, Ohtsu A, Tabernero J, Ilson DH, Hyung WJ, Strong VE, Goetze TO, Yoshikawa T, Tang LH, Hwang PMT, Webb N, Adelberg D, Shitara K. KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol 2019;15:943-52. [PMID: 30777447 DOI: 10.2217/fon-2018-0581] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
7 Reddavid R, Sofia S, Chiaro P, Colli F, Trapani R, Esposito L, Solej M, Degiuli M. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? World J Gastroenterol 2018; 24(2): 274-289 [PMID: 29375213 DOI: 10.3748/wjg.v24.i2.274] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 26] [Article Influence: 9.5] [Reference Citation Analysis]
8 Banerjee S, Zhao B, Sicklick JK, Aslam S, Burgoyne AM, Kelly KJ. Commission on Cancer Facility Type is Associated with Overall Survival in Patients with Gastric Adenocarcinoma in the United States. Ann Surg Oncol 2021;28:2846-55. [PMID: 33389292 DOI: 10.1245/s10434-020-09422-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Thiels CA, Ikoma N, Fournier K, Das P, Blum M, Estrella JS, Minsky BD, Ajani J, Mansfield P, Badgwell BD. Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol 2018;118:61-7. [PMID: 29878364 DOI: 10.1002/jso.25094] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
10 Rausei S, Lianos GD. Treatment of Gastric Cancer. Cancers (Basel) 2020;12:E2627. [PMID: 32942552 DOI: 10.3390/cancers12092627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhao B, Leichman LP, Horgan S, Bouvet M, Kelly KJ. Evaluation of treatment and outcomes for Hispanic patients with gastric cancer at Commission on Cancer‐accredited centers in the United States. J Surg Oncol 2019;119:941-7. [DOI: 10.1002/jso.25408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Moore JL, Davies AR, Santaolalla A, Van Hemelrijck M, Maisey N, Lagergren J, Gossage JA, Kelly M, Baker CR; Guy’s and St. Thomas’ Esophago-gastric Research Group. Clinical Relevance of the Tumor Location-Modified Laurén Classification System for Gastric Cancer in a Western Population. Ann Surg Oncol 2022. [PMID: 35041098 DOI: 10.1245/s10434-021-11252-y] [Reference Citation Analysis]
13 Biondi A, Agnes A, Del Coco F, Pozzo C, Strippoli A, D'Ugo D, Persiani R. Preoperative therapy and long-term survival in gastric cancer: One size does not fit all. Surg Oncol. 2018;27:575-583. [PMID: 30217321 DOI: 10.1016/j.suronc.2018.07.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
14 Rodrigues V, Landi F, Castro S, Mast R, Rodríguez N, Gantxegi A, Pradell J, López-Cano M, Armengol M. Is Sarcopenic Obesity an Indicator of Poor Prognosis in Gastric Cancer Surgery? A Cohort Study in a Western Population. J Gastrointest Surg 2021;25:1388-403. [PMID: 32661833 DOI: 10.1007/s11605-020-04716-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Pelc Z, Skórzewska M, Rawicz-Pruszyński K, Polkowski WP. Lymph Node Involvement in Advanced Gastric Cancer in the Era of Multimodal Treatment-Oncological and Surgical Perspective. Cancers (Basel) 2021;13:2509. [PMID: 34065596 DOI: 10.3390/cancers13102509] [Reference Citation Analysis]
16 Zhu Y, Sun X, Lin J, Zhang T, Liu X, Shen X. Investigating Potential Molecular Mechanisms of Carcinogenesis and Genes as Biomarkers for Prognosis of Gastric Cancer Based on Integrated Bioinformatics Analysis. Pathol Oncol Res 2019;25:1125-33. [PMID: 30430424 DOI: 10.1007/s12253-018-0523-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Agnes A, Biondi A, Laurino A, Strippoli A, Ricci R, Pozzo C, Persiani R, D'Ugo D. A detailed analysis of the recurrence timing and pattern after curative surgery in patients undergoing neoadjuvant therapy or upfront surgery for gastric cancer. J Surg Oncol 2020;122:293-305. [PMID: 32350878 DOI: 10.1002/jso.25959] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Hikage M, Fujiya K, Kamiya S, Tanizawa Y, Bando E, Notsu A, Terashima M. Prognostic factors in patients who received paraaortic lymph node dissection for locally advanced gastric cancer with extensive lymph node metastasis. Langenbecks Arch Surg 2022. [PMID: 35022832 DOI: 10.1007/s00423-021-02397-1] [Reference Citation Analysis]
19 Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, Feng JF, Ba Y, Liu YP, Li W, Shu YQ, Jiang Y, Li Q, Wang JW, Wu H, Feng H, Yao S, Xu RH. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019;30:1479-1486. [PMID: 31236579 DOI: 10.1093/annonc/mdz197] [Cited by in Crossref: 87] [Cited by in F6Publishing: 95] [Article Influence: 43.5] [Reference Citation Analysis]
20 Kinoshita T, Uyama I, Terashima M, Noshiro H, Nagai E, Obama K, Tamamori Y, Nabae T, Honda M, Abe T; LOC-A Study Group. Long-term Outcomes of Laparoscopic Versus Open Surgery for Clinical Stage II/III Gastric Cancer: A Multicenter Cohort Study in Japan (LOC-A Study). Ann Surg 2019;269:887-94. [PMID: 29697447 DOI: 10.1097/SLA.0000000000002768] [Cited by in Crossref: 48] [Cited by in F6Publishing: 17] [Article Influence: 24.0] [Reference Citation Analysis]
21 Nagaraja AK, Kikuchi O, Bass AJ. Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma. Cancer Discov 2019;9:1656-72. [PMID: 31727671 DOI: 10.1158/2159-8290.CD-19-0487] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
22 Datta J, Strong VE. Less may be more: shifting paradigm toward minimally invasive gastrectomy for locally advanced gastric cancer. Transl Gastroenterol Hepatol 2019;4:79. [PMID: 31872143 DOI: 10.21037/tgh.2019.09.12] [Reference Citation Analysis]
23 Bausys R, Bausys A, Stanaitis J, Vysniauskaite I, Maneikis K, Bausys B, Stratilatovas E, Strupas K. Propensity score-matched comparison of short-term and long-term outcomes between endoscopic submucosal dissection and surgery for treatment of early gastric cancer in a Western setting. Surg Endosc 2019;33:3228-37. [DOI: 10.1007/s00464-018-06609-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Griffin SM, Kamarajah SK, Navidi M, Wahed S, Immanuel A, Hayes N, Phillips AW. Evolution of gastrectomy for cancer over 30-years: Changes in presentation, management, and outcomes. Surgery 2021;170:2-10. [PMID: 33674126 DOI: 10.1016/j.surg.2021.01.040] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Lv L, Liang X, Wu D, Wang F, Zhang Y, Cang H, Deng X, Li M. Is cardia cancer a special type of gastric cancer? A differential analysis of early cardia cancer and non-cardia cancer. J Cancer 2021;12:2385-94. [PMID: 33758614 DOI: 10.7150/jca.51433] [Reference Citation Analysis]
26 Xu L, Chen X, Jiang H, Xu J, Wang L, Sun Y. NDUFC1 Is Upregulated in Gastric Cancer and Regulates Cell Proliferation, Apoptosis, Cycle and Migration. Front Oncol 2021;11:709044. [PMID: 34966665 DOI: 10.3389/fonc.2021.709044] [Reference Citation Analysis]
27 Shen L, Zhang P, Wang J, Ji P. Tac2-N serves an oncogenic role and promotes drug resistance in human gastric cancer cells. Exp Ther Med 2020;20:113. [PMID: 32989391 DOI: 10.3892/etm.2020.9241] [Reference Citation Analysis]
28 Liao X, Qian X, Zhang Z, Tao Y, Li Z, Zhang Q, Liang H, Li X, Xie Y, Zhuo R, Chen Y, Jiang Y, Cao H, Niu J, Xue C, Ni J, Pan J, Cui D. ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways. Front Oncol 2021;11:753119. [PMID: 34733788 DOI: 10.3389/fonc.2021.753119] [Reference Citation Analysis]
29 Raakow J, Denecke C, Chopra S, Fritz J, Hofmann T, Andreou A, Thuss-Patience P, Pratschke J, Biebl M. [Laparoscopic versus open gastrectomy for advanced gastric cancer : Operative and postoperative results]. Chirurg 2020;91:252-61. [PMID: 31654103 DOI: 10.1007/s00104-019-01053-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Liu J, Tian Z, Liu T, Wen D, Ma Z, Liu Y, Zhu J. CHSY1 is upregulated and acts as tumor promotor in gastric cancer through regulating cell proliferation, apoptosis, and migration. Cell Cycle 2021;20:1861-74. [PMID: 34412565 DOI: 10.1080/15384101.2021.1963553] [Reference Citation Analysis]
31 Cao Y, Wang J, Tian H, Fu GH. Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer. J Exp Clin Cancer Res 2020;39:119. [PMID: 32576206 DOI: 10.1186/s13046-020-01621-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
32 Brenkman HJ, Cho M, Ruurda JP, Song K, Son T, Kim H, Noh SH, van Hillegersberg R, Hyung WJ. European validation of the Yonsei Gastric Cancer Prognosis Prediction Model after gastrectomy: Validation with the Netherlands Cancer Registry. European Journal of Surgical Oncology 2019;45:983-8. [DOI: 10.1016/j.ejso.2019.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Pei Y, Tang Z, Cai M, Yao Q, Xie B, Zhang X. The E2F3/miR-125a/DKK3 regulatory axis promotes the development and progression of gastric cancer. Cancer Cell Int. 2019;19:212. [PMID: 31423109 DOI: 10.1186/s12935-019-0930-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
34 Beyer K, Baukloh AK, Kamphues C, Seeliger H, Heidecke CD, Kreis ME, Patrzyk M. Laparoscopic versus open gastrectomy for locally advanced gastric cancer: a systematic review and meta-analysis of randomized controlled studies. World J Surg Oncol 2019;17:68. [PMID: 30987645 DOI: 10.1186/s12957-019-1600-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 9.7] [Reference Citation Analysis]
35 Park JY, Verma A, Tran ZK, Mederos MA, Benharash P, Girgis M. Disparities in Utilization and Outcomes of Minimally Invasive Techniques for Gastric Cancer Surgery in the United States. Ann Surg Oncol. [DOI: 10.1245/s10434-021-11193-6] [Reference Citation Analysis]
36 Guo F, Xu Q, Lv Z, Ding HX, Sun LP, Zheng ZD, Yuan Y. Correlation Between TNFAIP2 Gene Polymorphism and Prediction/Prognosis for Gastric Cancer and Its Effect on TNFAIP2 Protein Expression. Front Oncol 2020;10:1127. [PMID: 32793480 DOI: 10.3389/fonc.2020.01127] [Reference Citation Analysis]
37 Kiudelis M, Rikterė A, Zviniene K, Mickevicius A, Maleckas A, Ivanauskas A, Endzinas Z. Laparoscopic versus open surgery for gastric cancer: the experience of one European centre. Prz Gastroenterol 2021;6:174-80. [PMID: 34276847 DOI: 10.5114/pg.2021.106670] [Reference Citation Analysis]
38 van der Veen A, Brenkman HJF, Seesing MFJ, Haverkamp L, Luyer MDP, Nieuwenhuijzen GAP, Stoot JHMB, Tegels JJW, Wijnhoven BPL, Lagarde SM, de Steur WO, Hartgrink HH, Kouwenhoven EA, Wassenaar EB, Draaisma WA, Gisbertz SS, van der Peet DL, May AM, Ruurda JP, van Hillegersberg R; LOGICA Study Group. Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): A Multicenter Randomized Clinical Trial. J Clin Oncol 2021;39:978-89. [PMID: 34581617 DOI: 10.1200/JCO.20.01540] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
39 Ham IH, Oh HJ, Jin H, Bae CA, Jeon SM, Choi KS, Son SY, Han SU, Brekken RA, Lee D, Hur H. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. Mol Cancer. 2019;18:68. [PMID: 30927911 DOI: 10.1186/s12943-019-0972-8] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 16.0] [Reference Citation Analysis]
40 Zhang M, Ding C, Xu L, Ou B, Feng S, Wang G, Wang W, Liang Y, Chen Y, Zhou Z, Qiu H. Comparison of a Tumor-Ratio-Metastasis Staging System and the 8th AJCC TNM Staging System for Gastric Cancer. Front Oncol 2021;11:595421. [PMID: 34307116 DOI: 10.3389/fonc.2021.595421] [Reference Citation Analysis]
41 Li P, Huang CM, Zheng CH, Russo A, Kasbekar P, Brennan MF, Coit DG, Strong VE. Comparison of gastric cancer survival after R0 resection in the US and China. J Surg Oncol. 2018;118:975-982. [PMID: 30332517 DOI: 10.1002/jso.25220] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
42 Sun W, Jiang C, Ji Y, Xiao C, Song H. Long Noncoding RNAs: New Regulators of Resistance to Systemic Therapies for Gastric Cancer. Biomed Res Int 2021;2021:8853269. [PMID: 33506041 DOI: 10.1155/2021/8853269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
43 Yang L, Wang X, Wang B, Chao P, Li D, Chai C. The clinical outcomes of S-1 plus cisplatin for patients with advanced gastric cancer: A meta-analysis and systematic review. Medicine (Baltimore) 2018;97:e12789. [PMID: 30544367 DOI: 10.1097/MD.0000000000012789] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]